NO20060813L - Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav - Google Patents

Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav

Info

Publication number
NO20060813L
NO20060813L NO20060813A NO20060813A NO20060813L NO 20060813 L NO20060813 L NO 20060813L NO 20060813 A NO20060813 A NO 20060813A NO 20060813 A NO20060813 A NO 20060813A NO 20060813 L NO20060813 L NO 20060813L
Authority
NO
Norway
Prior art keywords
neu
hher2
gene encoding
optimized
codon
Prior art date
Application number
NO20060813A
Other languages
English (en)
Norwegian (no)
Inventor
Pasquale Gallo
Paolo Monaci
Maurizio Nuzzo
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of NO20060813L publication Critical patent/NO20060813L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20060813A 2003-07-21 2006-02-20 Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav NO20060813L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48923703P 2003-07-21 2003-07-21
PCT/EP2004/008234 WO2005012527A1 (en) 2003-07-21 2004-07-20 Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof

Publications (1)

Publication Number Publication Date
NO20060813L true NO20060813L (no) 2006-03-20

Family

ID=34115329

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060813A NO20060813L (no) 2003-07-21 2006-02-20 Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav

Country Status (14)

Country Link
US (2) US20070111957A1 (zh)
EP (1) EP1649020B1 (zh)
JP (1) JP4772674B2 (zh)
KR (1) KR101141507B1 (zh)
CN (2) CN101173282B (zh)
AU (1) AU2004261724B2 (zh)
CA (1) CA2532460C (zh)
IL (1) IL173208A (zh)
IS (1) IS8200A (zh)
NO (1) NO20060813L (zh)
NZ (1) NZ544543A (zh)
RU (1) RU2397249C2 (zh)
WO (1) WO2005012527A1 (zh)
ZA (1) ZA200600248B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061462B1 (en) 2007-07-02 2019-02-27 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
CN103555765B (zh) * 2013-05-30 2015-01-07 中南大学湘雅医院 一种转录调控肿瘤靶向复制溶瘤腺病毒载体、携带治疗基因腺病毒及其制备方法和应用
KR102509481B1 (ko) * 2014-04-10 2023-03-10 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 규정된 조성물 유전자 변형된 t-세포 생성물
WO2016112188A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for ebola virus vaccination
KR102193635B1 (ko) 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
CN108174604B (zh) 2015-08-07 2023-06-23 西雅图儿童医院（Dba西雅图儿童研究所） 用于实体瘤靶向的双特异性car t细胞
JP7171433B2 (ja) 2015-10-30 2022-11-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法
CN110291200B (zh) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
SG11202001115TA (en) * 2017-08-24 2020-03-30 Bavarian Nordic As Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody
CN112941132B (zh) * 2021-05-17 2021-07-23 烟台市华昕生物医药科技有限公司 一种利用大肠杆菌表达寡肽-1的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0758196A4 (en) * 1994-05-05 1999-05-06 Univ Pennsylvania COMPOSITIONS AND METHODS FOR TREATING TUMORS
IT1276662B1 (it) * 1995-04-04 1997-11-03 Uni Degli Studi Camerino Vaccini polinucleotidici
DE60044665D1 (de) * 1999-01-29 2010-08-26 Corixa Corp Her2/neu fusionsproteine
CN1537164A (zh) * 2000-08-14 2004-10-13 治疗和诊断Her-2/neu相关恶性肿瘤的组合物和方法
WO2002022080A2 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
CN1164330C (zh) * 2001-07-19 2004-09-01 中国医学科学院基础医学研究所 一种重组复制缺陷型腺病毒载体狂犬病毒基因工程疫苗
KR100555211B1 (ko) * 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신
WO2004041065A2 (en) * 2002-10-30 2004-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS
US7282365B2 (en) 2003-01-03 2007-10-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Rhesus HER2/neu, nucleotides encoding same, and uses thereof

Also Published As

Publication number Publication date
WO2005012527A1 (en) 2005-02-10
RU2397249C2 (ru) 2010-08-20
JP4772674B2 (ja) 2011-09-14
CA2532460A1 (en) 2005-02-10
IS8200A (is) 2005-12-27
RU2006105195A (ru) 2006-06-27
AU2004261724B2 (en) 2010-06-17
WO2005012527A9 (en) 2006-03-02
KR101141507B1 (ko) 2012-05-08
KR20060052852A (ko) 2006-05-19
CN1826409A (zh) 2006-08-30
EP1649020B1 (en) 2017-01-11
EP1649020A1 (en) 2006-04-26
CA2532460C (en) 2012-04-24
AU2004261724A1 (en) 2005-02-10
ZA200600248B (en) 2007-03-28
US7662586B2 (en) 2010-02-16
IL173208A (en) 2014-06-30
CN100558894C (zh) 2009-11-11
US20090098604A1 (en) 2009-04-16
IL173208A0 (en) 2006-06-11
CN101173282B (zh) 2011-04-06
CN101173282A (zh) 2008-05-07
NZ544543A (en) 2009-03-31
JP2006527989A (ja) 2006-12-14
US20070111957A1 (en) 2007-05-17

Similar Documents

Publication Publication Date Title
NO20060813L (no) Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav
NO20055708L (no) Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav
IL177277A0 (en) Carcinoembryonic antigen fusions proteins and uses thereof
Liu et al. Telomerase in cancer immunotherapy
ES2676630T3 (es) Control inmunogénico de tumores y células tumorales
Wang et al. Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen
DE602004027902D1 (de) Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
HUP0105303A2 (en) Her-2/neu fusion proteins
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
IL198012A0 (en) Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
MX2023014457A (es) Peptidos antigenicos para la prevencion y el tratamiento del cancer.
Hage et al. TAP expression level in tumor cells defines the nature and processing of MHC class I peptides for recognition by tumor‐specific cytotoxic T lymphocytes
Nelson et al. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the ‘self’tumor-associated antigen, neu in a rat mammary tumor model
Park et al. Effective immunotherapy of cancer by DNA vaccination
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
EP1536006A4 (en) CANCER-ANIMALS AND THEIR USE
HUP0204216A2 (en) A new use of antibodies as vaccines
Biragyn et al. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
Odales et al. Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer
Luo et al. FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice
RU2020100072A (ru) Иммуногенные композиции, содержащие cea, muc1 и tert
Deng et al. A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MSD ITALIA SRL, IT

FC2A Withdrawal, rejection or dismissal of laid open patent application